Embargoed Release: 07:00hrs Wednesday 25 June 2008
Sopheon plc
("Sopheon" or the "Company")
Sopheon Achieves Growth Milestone with
Signing of 150th Licensee Customer
Novartis, Burger King Corp. and U.S. Army
Among Latest Organisations to Select Sopheon Software
MINNEAPOLIS and LONDON─June 25, 2008 ─ Sopheon, the international provider of
software and services for product lifecycle management, announced today that
150 customers have now licensed its software products. Recent signees include
Novartis, the world's fifth-largest pharmaceutical company, Burger King Corp.,
the second largest fast-food hamburger chain in the world with more than 11,400
restaurants in all 50 U.S. states and 70 countries and U.S. territories, and
the U.S. Army. Sopheon entered 2008 with 135 licensees.
Recent orders have continued to add to the company's already promising
performance outlook for 2008. Earlier this month, in a statement to attendees
of its annual general meeting for shareholders, Sopheon announced that revenue
visibility for the full year 2008 already stood at £5.7 million. Based on
business activity since the meeting, such visibility has now increased to more
than £6 million. Visibility at any point in time comprises revenue expected
from (i) closed license orders, including those which are contracted but
conditional on acceptance decisions scheduled later in the year; (ii)
contracted services business delivered or expected to be delivered in the year;
and (iii) recurring maintenance, hosting and rental streams. The visibility
calculation does not include revenues from new sales opportunities expected to
close during the remainder of 2008. The company's pipeline of such prospective
business remains very active. Sopheon's revenues for all of 2007 totaled £6.3
million.
"Today's milestone punctuates a historic pattern of substantial growth," said
Barry Mence, chairman of Sopheon's board of directors. "Since 2001, reported
revenues from our core business have increased by an average of 41% in U.S.
dollars annually. This record has been achieved despite periods of economic
uncertainty and escalating competition. Our success obviously reflects the
appeal of our solutions and their benefits. But it is also rooted in the
quality of our people, and the passion and dedication that they bring to every
aspect of our effort to deliver exceptional value to our customers. I couldn't
be more proud of what they have accomplished."
For further information contact:
Barry Mence, Chairman Sopheon plc + 44 (0) 1483 685 735
Arif Karimjee, CFO
Vikki Krause Hansard Communications + 44 (0) 207 245 1100
+ 44 (0) 7957 203 685
Claire Verhagen Citigate First Financial + 31 (0) 205 754 010
Paul Davies, Seymour Pierce + 44 (0) 207 107 8000
Corporate Finance
Richard Redmayne,
Corporate Broking
About Sopheon
Sopheon (LSE:SPE) is an international provider of software and services that
help organizations improve the business impact of product innovation. Sopheon's
solutions automate and govern the innovation process, enabling companies to
increase revenue and profits from new products. Sopheon is listed on the AIM
Market of the London Stock Exchange and on the Euronext in the Netherlands. For
more information, please visit www.sopheon.com.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.